Kuangli Bio-Tech Holdings Co (TPE:6431) Ending Cash Position: NT$188.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6431 Kuangli Bio-Tech Holdings Co Ltd TPE:6431
65 GF Score
Price NT$19.65
GF Value NT$10.62
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Kuangli Bio-Tech Holdings Co Ending Cash Position?

Kuangli Bio-Tech Holdings Co TPE:6431 -3.20% 65 Ending Cash Position is NT$188.0 Mil as of Mar. 2026. GuruFocus rates TPE:6431 with a GF Score™ of 65/100 and a GF Value™ of NT$10.62 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Kuangli Bio-Tech Holdings Co's Ending Cash Position for the quarter that ended in Mar. 2026 was NT$188.0 Mil.

Kuangli Bio-Tech Holdings Co's quarterly Ending Cash Position increased from Sep. 2025 (NT$187.3 Mil) to Dec. 2025 (NT$208.9 Mil) but then declined from Dec. 2025 (NT$208.9 Mil) to Mar. 2026 (NT$188.0 Mil).

Kuangli Bio-Tech Holdings Co's annual Ending Cash Position declined from Dec. 2023 (NT$63.2 Mil) to Dec. 2024 (NT$41.6 Mil) but then increased from Dec. 2024 (NT$41.6 Mil) to Dec. 2025 (NT$208.9 Mil).

Kuangli Bio-Tech Holdings Co Ending Cash Position Related Terms

Kuangli Bio-Tech Holdings Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Kuangli Bio-Tech Holdings Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kuangli Bio-Tech Holdings Co Ending Cash Position Chart

Kuangli Bio-Tech Holdings Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 162.17 141.89 63.22 41.59 208.93

Kuangli Bio-Tech Holdings Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 331.98 292.30 187.32 208.93 188.04
TPE:6431
65GF Score
Kuangli Bio-Tech Holdings Co Ltd TPE:6431
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kuangli Bio-Tech Holdings Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Kuangli Bio-Tech Holdings Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=41.586+167.344
=208.9

Kuangli Bio-Tech Holdings Co's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=208.93+-20.889
=188.0

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of NT$188.0 Mil mean?
Kuangli Bio-Tech Holdings Co (TPE:6431) has a Ending Cash Position of NT$188.0 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Kuangli Bio-Tech Holdings Co and its competitors.
Is Kuangli Bio-Tech Holdings Co's Ending Cash Position too high?
Kuangli Bio-Tech Holdings Co's current Ending Cash Position is NT$188.0 Mil. Overall, Kuangli Bio-Tech Holdings Co has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kuangli Bio-Tech Holdings Co's Ending Cash Position compare to PG and CL?
Kuangli Bio-Tech Holdings Co's Ending Cash Position of NT$188.0 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Consumer Packaged Goods company?
A good Ending Cash Position depends on the Consumer Packaged Goods industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Kuangli Bio-Tech Holdings Co and its competitors. Kuangli Bio-Tech Holdings Co's current Ending Cash Position is NT$188.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuangli Bio-Tech Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Kuangli Bio-Tech Holdings Co (TPE:6431) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$10.62, compared to a current price of NT$19.65 — trading 85% above its estimated fair value. The current Ending Cash Position is NT$188.0 Mil. Kuangli Bio-Tech Holdings Co's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Kuangli Bio-Tech Holdings Co (TPE:6431), the current Ending Cash Position is NT$188.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kuangli Bio-Tech Holdings Co (TPE:6431) Overvalued in 2026?

Based on GuruFocus' analysis, Kuangli Bio-Tech Holdings Co stock appears to be overvalued. The current stock price of NT$19.65 is trading 85% above its estimated GF Value™ of NT$10.62. GuruFocus considers Kuangli Bio-Tech Holdings Co to be Significantly Overvalued.

Key valuation signals for TPE:6431:

  • Ending Cash Position: NT$188.0 Mil
  • GF Value™: NT$10.62 vs. price of NT$19.65 (85% above fair value)
  • GF Score™: 65/100 with 8 warning signs

No single metric tells the full story. See the TPE:6431 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kuangli Bio-Tech Holdings Co Business Description

Address North Sound Road, Suite 102, Cannon Place, George Town, Grand Cayman, CYM
Kuangli Bio-Tech Holdings Co Ltd is mainly engaged in the manufacture and trading of various types of panels (LENS), such as mobile phone panels, digital camera windows, PDA panels, and instrument panels. The company is also engaged in the development, manufacturing and trading of cosmetics and skin care products and other related biotechnology products. It derives revenue from Health and Wellness products, and Cosmetics and skin care products, including Lotion, Facial masks, and Other pastes. The primary source of revenue for the company is sales of cosmetic products.
65GF Score

Get the complete analysis for TPE:6431

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$19.65
Price
NT$10.62
GF Value